ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Epstein-Barr virus (EBV)"

  • 2021 American Transplant Congress

    Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant

    S. Prockop1, L. Gamelin2, R. Dinavahi2, Y. Sun2, N. Guzman-Becerra2, H. Parmar2

    1Memorial Sloan Kettering Cancer Center, New York, NY, 2Atara Biotherapeutics, South San Francisco, CA

    *Purpose: Tabelecleucel is an investigational, off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy being studied in patients (pts) with serious EBV-driven diseases, including post-transplant lymphoproliferative disease…
  • 2021 American Transplant Congress

    T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients

    S. Kothari, T. Ku, D. Kumar, A. Humar, V. H. Ferreira

    Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada

    *Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…
  • 2020 American Transplant Congress

    Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation

    M. Yamada, A. Fukuda, M. Ogura, S. Shimizu, Y. Ishikawa, F. Kawano, H. Uchida, M. Takeda, Y. Yanagi, S. Sakamoto, M. Kasahara, K. Imadome

    National Center for Child Health and Development, Tokyo, Japan

    *Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…
  • 2020 American Transplant Congress

    Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort

    K. Jackson1, O. Martinez2, S. Krams2, M. Robien3, M. Lapasaran2, B. Armstrong4, C. Twist5, K. Weinberg6, D. Gratzinger1, B. Tam1, M. Sever4, M. Brown3, D. Bernstein6, C. Esquivel2, S. D. Boyd1

    1Department of Pathology, Stanford Univ School of Med, Stanford, CA, 2Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, 3NIAID, NIH, Bethesda, MD, 4Rho, Chapel Hill, NC, 5Roswell Park, Buffalo, NY, 6Department of Pediatrics, Stanford Univ School of Med, Stanford, CA

    *Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…
  • 2020 American Transplant Congress

    Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database

    W. S. Cherikh1, T. Kou2, J. Foutz1, A. Gomez-Caminero2

    1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ

    *Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…
  • 2020 American Transplant Congress

    Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study

    S. Prockop1, R. Reshaf2, D. Tsai3, N. Bunin4, R. Abu-Arja5, K. Mahadeo6, W. Weng7, K. Van Besien8, D. Loeb9, S. Dwivedy Nasta10, E. Nemecek11, M. Hiremath12, S. Yue12, Y. Sun12, W. Navarro12, S. Nikiforow13

    1Memorial Sloan Kettering Cancer Center, New York, NY, 2Columbia University Irving Medical Center, New York, NY, 3Loxo Oncology, Stamford, CT, 4The Children's Hospital of Philadelphia, Philadelphia, PA, 5Nationwide Children's Hospital, Columbus, OH, 6MD Anderson Cancer Center, Houston, TX, 7Stanford University School of Medicine, California, CA, 8Weill Cornell Medical College, New York, NY, 9Children's Hospital at Montefiore, Bronx, NY, 10University of Pennsylvania, Philadelphia, PA, 11Oregon Health & Science University, Portland, OR, 12Atara Biotherapeutics, New York, NY, 13Dana Farber Cancer Institute, Boston, MA

    *Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
  • 2020 American Transplant Congress

    Genome-Wide Analysis of Epstein Barr Virus Identifies Variations in the Latency Gene EBNA3C That Are Associated with Post Transplant Lymphoproliferative Disorder

    E. Maloney, J. Toh, S. M. Krams, C. O. Esquivel, O. M. Martinez

    Stanford University Sch of Med, Stanford, CA

    *Purpose: Epstein Barr virus (EBV) is a gamma herpes virus that is associated with a variety of human malignancies including EBV+ B cell lymphomas in…
  • 2020 American Transplant Congress

    Role of CAR-T Cell Therapy in Post Transplant Lymphoproliferative Disorder

    S. Krishnamoorthy, A. Malone, R. Delos Santos, H. Murad, T. Alhamad

    Transplant, Washington University in St. Louis, Saint Louis, MO

    *Purpose: Chimeric Antigen Receptor (CAR) T cells are a genetically modified autologous immunotherapy that uses a patient’s own T cells modified with a chimeric antigen…
  • 2020 American Transplant Congress

    Valganciclovir for Epstein-Barr Virus Prevention after Pediatric Kidney Transplant

    R. Jackson1, S. Mehra2, E. Smith1, C. Peterson2, E. Benefield1, R. Ensign1, J. Sherbotie2, C. Heyrend1

    1Intermountain Healthcare, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    *Purpose: Epstein-Barr virus (EBV) infection after pediatric kidney transplant (pKTx) is common and can lead to post transplant lymphoproliferative disorder (PTLD). Valganciclovir (VGN) is used…
  • 2020 American Transplant Congress

    Vira-ome: A Tool for an Unbiased Plasma Virome Analysis of SOT Recipients from Cell-Free DNA Sequences

    R. Sinha, E. Bixler, J. Grantham, M. Altrich, S. Kleiboeker

    R&D, Viracor-Eurofins, Lee's Summit, MO

    *Purpose: Blood virome of healthy individuals is frequently predominated by member of families such as Herpesvirus, Anellovirus and Polyomaviridae. The viral load of commensal species…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences